Work

Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China

Year: 2024

Type: article

Abstract: BACKGROUND: To evaluate the cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma (ESCC) from the perspective of the Chinese health service system. METHODS: A partitioned survival model was constructed to simulate quality-adjusted life years and incremental cost-effectiveness ratios over a patient's lifetime based on a phase III clinical trial. RESULTS: Sintilimab plus chemotherapy increased by 0.316 QALY and 0.285 QALY with the additional cost of $5692 and $5269, which led to the ICER of $18000/QALY and $18519/QALY gained in the overall population and the patients with CPS ≥ 10, respectively. CONCLUSIONS: Compared with chemotherapy alone, sintilimab may be a cost-effective first-line treatment choice for locally advanced or metastatic ESCC.

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2024.2410248

Authors: Nanlong Lin, Shiting Chen, Zhiwei Zheng, Xiaobing Song

Institutions: Fujian Medical University, First Affiliated Hospital of Fujian Medical University, Cancer Hospital of Shantou University Medical College

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Guangdong Medical Research Foundation